HRP20201710T1 - Tolerogeno dna cjepivo - Google Patents
Tolerogeno dna cjepivo Download PDFInfo
- Publication number
- HRP20201710T1 HRP20201710T1 HRP20201710TT HRP20201710T HRP20201710T1 HR P20201710 T1 HRP20201710 T1 HR P20201710T1 HR P20201710T T HRP20201710T T HR P20201710TT HR P20201710 T HRP20201710 T HR P20201710T HR P20201710 T1 HRP20201710 T1 HR P20201710T1
- Authority
- HR
- Croatia
- Prior art keywords
- plasmid
- sequence
- tgf
- encodes
- sequence encoding
- Prior art date
Links
- 230000003614 tolerogenic effect Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 239000013612 plasmid Substances 0.000 claims 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 7
- 102000004877 Insulin Human genes 0.000 claims 6
- 108090001061 Insulin Proteins 0.000 claims 6
- 229940125396 insulin Drugs 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 229940032219 immunotherapy vaccine Drugs 0.000 claims 5
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 2
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108010066381 preproinsulin Proteins 0.000 claims 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010076181 Proinsulin Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000014621 translational initiation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/60—Vectors containing traps for, e.g. exons, promoters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Claims (14)
1. Plazmid, naznačen time što kodira:
i. inzulinski antigen;
ii. TGF-β;
iii. IL-10; i
gdje navedeni plazmid dodatno pogoni ekspresiju interleukina-2 (IL-2).
2. Plazmid u skladu s patentnim zahtjevom 1, naznačen time što se navedeni inzulinski antigen bira iz skupine koju čine: proinzulin, preproinzulin, te njegov funkcionalni ili imunodominantni peptidni fragment.
3. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni inzulinski antigen endosomno ciljani inzulin.
4. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni plazmid pogoni ekspresiju inzulinskog antigena i TGF-β u količini najmanje 2 puta manjoj nego IL-10.
5. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni plazmid sadrži: (i) FMDV 2A element koji razdvaja slijed koji kodira inzulinski antigen i slijed koji kodira TGF-β, (ii) EMCV IRES element koji razdvaja slijed koji kodira TGF-β i slijed koji kodira IL-10, te (iii) 2A element koji razdvaja slijed koji kodira IL-10 i slijed koji kodira IL-2.
6. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što slijed koji kodira TGF-β kodira konstitutivno aktivni TGF-β.
7. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni plazmid sadrži: (i) endosomno ciljani slijed koji kodira preproinzulin, (ii) FMDV 2A element, (iii) slijed koji kodira TGF-β, (iv) EMCV IRES element, (v) slijed koji kodira IL-10, (vi) P 2A element, (vii) slijed koji kodira IL-2, (viii) poliadenilacijski/terminacijski element, (ix) selekcijski gen, (x) početak replikacije, (xi) eukariotski promotorski element, (xii) eukariotski slijed za početak translacije, (xiii) slijed za endosomsko sortiranje sequence, te (xiv) izborno intron.
8. DNA imunoterapijsko cjepivo, naznačeno time što sadrži plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva.
9. DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što su namijenjeni upotrebi u odgađanju ili sprječavanju dijabetesa tip I.
10. DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što su namijenjeni supkutanoj primjeni.
11. DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što su namijenjeni intramuskularnoj primjeni.
12. Farmaceutski pripravak, naznačen time što sadrži DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što navedeni farmaceutski pripravak sadrži fiziološku otopinu i/ili pufer i/ili kelator.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što navedeni pufer ne sadrži viruse, lipidna sredstva za supakiranje ili kondenzacijska sredstva.
14. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 12-13, naznačen time što navedeni pripravak dodatno sadrži agonist GLP-1R.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662415717P | 2016-11-01 | 2016-11-01 | |
EP17150037 | 2017-01-02 | ||
EP17169019 | 2017-05-02 | ||
EP17177289 | 2017-06-22 | ||
EP17198041 | 2017-10-24 | ||
PCT/EP2017/077949 WO2018083111A1 (en) | 2016-11-01 | 2017-11-01 | Tolerogenic dna vaccine |
EP17801363.7A EP3534936B1 (en) | 2016-11-01 | 2017-11-01 | Tolerogenic dna vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201710T1 true HRP20201710T1 (hr) | 2020-12-25 |
Family
ID=60190888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201710TT HRP20201710T1 (hr) | 2016-11-01 | 2020-10-23 | Tolerogeno dna cjepivo |
Country Status (24)
Country | Link |
---|---|
US (1) | US11466278B2 (hr) |
EP (3) | EP3534936B1 (hr) |
JP (3) | JP7084388B2 (hr) |
KR (1) | KR102476552B1 (hr) |
CN (3) | CN109922827B (hr) |
AU (1) | AU2017353323B2 (hr) |
BR (1) | BR112019007408A2 (hr) |
CA (1) | CA3042321A1 (hr) |
CL (1) | CL2019001181A1 (hr) |
CO (1) | CO2019004193A2 (hr) |
DK (1) | DK3534936T3 (hr) |
ES (2) | ES2829574T3 (hr) |
HR (1) | HRP20201710T1 (hr) |
HU (1) | HUE051766T2 (hr) |
IL (1) | IL266237B (hr) |
MX (1) | MX2019004774A (hr) |
MY (1) | MY190102A (hr) |
PE (1) | PE20190841A1 (hr) |
PH (1) | PH12019500851A1 (hr) |
PL (1) | PL3534936T3 (hr) |
RS (1) | RS61138B1 (hr) |
RU (1) | RU2752608C2 (hr) |
SA (1) | SA519401615B1 (hr) |
SI (1) | SI3534936T1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
IL266237B (en) * | 2016-11-01 | 2022-08-01 | Novo Nordisk As | Tolerogenic DNA composition |
US11279745B2 (en) | 2019-04-26 | 2022-03-22 | Novo Nordisk A/S | Tolerogenic DNA vaccine |
CN113461796A (zh) * | 2021-08-04 | 2021-10-01 | 深圳晶蛋生物医药科技有限公司 | 一种重组sglt2蛋白及其应用 |
CN118139655A (zh) * | 2021-08-13 | 2024-06-04 | 特里奥万斯控股公司 | 皮肤替代组合物及其产生和使用方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518395D0 (en) * | 1995-09-08 | 1995-11-08 | Therexsys Ltd | Plasmid stabilization |
US6083919A (en) | 1996-12-05 | 2000-07-04 | University Of Florida | Materials and methods for treating autoimmune disease |
US7030098B2 (en) | 1999-03-12 | 2006-04-18 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for treatment of autoimmune disease |
US6884785B2 (en) | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
AU2001253746A1 (en) | 2000-04-20 | 2001-11-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Inducible plasmid vector encoding tgf-beta and uses thereof |
EP2329846B1 (en) * | 2000-09-08 | 2014-11-12 | University Of Maryland, Baltimore | Genetically engineered co-expression DNA vaccines, construction methods and uses thereof |
USD459798S1 (en) | 2001-03-26 | 2002-07-02 | Aventis Pharma S.A. | Pill tablet |
SE0102204D0 (sv) | 2001-06-21 | 2001-06-21 | Leif Isaksson | New method |
US7544669B2 (en) | 2001-11-21 | 2009-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
AU2003278695A1 (en) | 2002-05-28 | 2004-02-02 | Maxygen, Inc. | Nucleic acid vectors |
RU2228198C1 (ru) * | 2002-08-21 | 2004-05-10 | Полетаев Александр Борисович | Способ коррекции патологического аутоиммунного процесса при сахарном диабете |
EP2322186A3 (en) | 2002-11-21 | 2011-07-13 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
US20050026189A1 (en) | 2003-05-29 | 2005-02-03 | Liangsu Wang | Microbial operons |
US20050147621A1 (en) | 2003-10-10 | 2005-07-07 | Higgins Darren E. | Use of bacterial 5' untranslated regions for nucleic acid expression |
WO2005089101A2 (en) | 2004-02-03 | 2005-09-29 | Dana-Farber Cancer Institute, Inc. | Non-pathogenic listeria vaccine vectors and methods of treatment therewith |
CN101277722A (zh) * | 2005-08-06 | 2008-10-01 | 王庆华 | 用于预防和治疗ⅰ型糖尿病的组合物及方法 |
CN101365494A (zh) | 2005-10-05 | 2009-02-11 | 贝希尔治疗学股份有限公司 | 治疗自身免疫性疾病的组合物和方法 |
CA2550133A1 (en) | 2006-02-16 | 2007-08-16 | The Governors Of The University Of Alberta | Temperature regulated gene expression |
US20100048679A1 (en) | 2006-06-13 | 2010-02-25 | Bayhill Therapeutics, Inc. | Polynucleotide therapy |
US9339500B2 (en) | 2008-03-04 | 2016-05-17 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
US9217153B2 (en) | 2009-05-22 | 2015-12-22 | Merial, Inc. | Antibiotic-free plasmids |
AU2010278702C1 (en) | 2009-07-31 | 2016-07-14 | Forsyth Dental Infirmary For Children | Programming of cells for tolerogenic therapies |
JP2013517329A (ja) | 2010-01-20 | 2013-05-16 | ベイヒル セラピューティクス インコーポレーティッド | 自己免疫疾患を処置するための併用治療 |
CN103200959A (zh) | 2010-09-27 | 2013-07-10 | 中国农业大学 | 预防和治疗自身免疫性疾病的联合抗原和dna疫苗 |
WO2012062697A1 (en) * | 2010-11-08 | 2012-05-18 | Novartis Ag | Combination therapy for type 1 diabetes |
EP2753362A4 (en) | 2011-09-08 | 2015-04-15 | Univ Florida | MATERIALS AND METHODS FOR MODULATING THE IMMUNE RESPONSE |
WO2014035457A1 (en) | 2012-08-29 | 2014-03-06 | Nature Technology Corporation | Dna plasmids with improved expression |
US9636386B2 (en) | 2013-03-15 | 2017-05-02 | City Of Hope | Attenuated Salmonella bacteria and methods of using |
WO2016057986A1 (en) * | 2014-10-10 | 2016-04-14 | The Trustees Of Columbia University In The City Of New York | Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof |
WO2016162385A1 (en) | 2015-04-07 | 2016-10-13 | Consejo Superior De Investigaciones Científicas (Csic) | Bacterial system for the identification of amyloidogenic peptides and the screening of inhibitors of amyloidosis |
EP3556847B1 (de) | 2015-12-11 | 2021-03-03 | Wacker Chemie AG | Mikroorganismenstamm und verfahren zur antibiotikafreien, fermentativen herstellung von niedermolekularen substanzen und proteinen |
IL266237B (en) * | 2016-11-01 | 2022-08-01 | Novo Nordisk As | Tolerogenic DNA composition |
TWI728201B (zh) | 2016-11-01 | 2021-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 耐受性dna疫苗 |
USD813372S1 (en) | 2017-02-22 | 2018-03-20 | Celgene Corporation | Pharmaceutical tablet |
US11279745B2 (en) | 2019-04-26 | 2022-03-22 | Novo Nordisk A/S | Tolerogenic DNA vaccine |
-
2017
- 2017-11-01 IL IL266237A patent/IL266237B/en unknown
- 2017-11-01 HU HUE17801363A patent/HUE051766T2/hu unknown
- 2017-11-01 CN CN201780068074.0A patent/CN109922827B/zh active Active
- 2017-11-01 MX MX2019004774A patent/MX2019004774A/es unknown
- 2017-11-01 BR BR112019007408A patent/BR112019007408A2/pt unknown
- 2017-11-01 MY MYPI2019002005A patent/MY190102A/en unknown
- 2017-11-01 ES ES17791421T patent/ES2829574T3/es active Active
- 2017-11-01 PE PE2019000889A patent/PE20190841A1/es unknown
- 2017-11-01 AU AU2017353323A patent/AU2017353323B2/en active Active
- 2017-11-01 KR KR1020197015401A patent/KR102476552B1/ko active IP Right Grant
- 2017-11-01 ES ES17801363T patent/ES2834329T3/es active Active
- 2017-11-01 EP EP17801363.7A patent/EP3534936B1/en active Active
- 2017-11-01 RS RS20201421A patent/RS61138B1/sr unknown
- 2017-11-01 JP JP2019522789A patent/JP7084388B2/ja active Active
- 2017-11-01 EP EP17791421.5A patent/EP3535399B1/en active Active
- 2017-11-01 SI SI201730504T patent/SI3534936T1/sl unknown
- 2017-11-01 CA CA3042321A patent/CA3042321A1/en active Pending
- 2017-11-01 JP JP2019522762A patent/JP6721790B2/ja active Active
- 2017-11-01 CN CN202410173247.7A patent/CN118086388A/zh active Pending
- 2017-11-01 RU RU2019115540A patent/RU2752608C2/ru active
- 2017-11-01 EP EP20201771.1A patent/EP3799882A1/en not_active Withdrawn
- 2017-11-01 US US16/341,940 patent/US11466278B2/en active Active
- 2017-11-01 DK DK17801363.7T patent/DK3534936T3/da active
- 2017-11-01 PL PL17801363T patent/PL3534936T3/pl unknown
- 2017-11-01 CN CN201780067813.4A patent/CN109890967B/zh active Active
-
2019
- 2019-04-17 PH PH12019500851A patent/PH12019500851A1/en unknown
- 2019-04-18 SA SA519401615A patent/SA519401615B1/ar unknown
- 2019-04-26 CO CONC2019/0004193A patent/CO2019004193A2/es unknown
- 2019-04-29 CL CL2019001181A patent/CL2019001181A1/es unknown
-
2020
- 2020-01-29 JP JP2020012426A patent/JP2020062057A/ja active Pending
- 2020-10-23 HR HRP20201710TT patent/HRP20201710T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201710T1 (hr) | Tolerogeno dna cjepivo | |
RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
Zhou et al. | Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung | |
EP2215269B1 (en) | Construct system and uses therefor | |
JP2019532659A5 (hr) | ||
JP2015166353A5 (hr) | ||
AU2019250180A1 (en) | CMV glycoproteins and recombinant vectors | |
HRP20211566T1 (hr) | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe | |
JP2018524393A5 (hr) | ||
JP2020528911A5 (hr) | ||
JP2006512097A5 (hr) | ||
JP2017530124A5 (hr) | ||
CA3087442A1 (en) | Formulation for administration of rna | |
JP2021509107A (ja) | B型肝炎ウイルス(hbv)ワクチンおよびその使用 | |
AU2017297822A1 (en) | Formulation for administration of RNA | |
EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
Robertsen et al. | IFN-adjuvanted DNA vaccine against infectious salmon anemia virus: Antibody kinetics and longevity of IFN expression | |
WO2013067652A1 (en) | Facilitator-dna combination vaccine | |
RU2021109510A (ru) | Вакцинация с использованием альфа 3 домена mica/b для лечения рака | |
WO2005046621A3 (en) | Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines | |
Pedersen et al. | Stimulation of type I IFN activity in Atlantic salmon (Salmo salar L.) leukocytes: synergistic effects of cationic proteins and CpG ODN | |
KR20240023600A (ko) | 바이러스 질환을 위한 온도-제어가능한, 자기-복제 rna 백신 | |
JP2017516462A5 (hr) | ||
JP2013512256A5 (hr) | ||
JP2010510218A5 (hr) |